Cancer Treatment in China for Vietnamese Patients: What Families Need to Know
Vietnam is geographically closer to China than any other country in this guide — a two-and-a-half-hour flight from Hanoi to Beijing — yet access to advanced blood cancer treatments including CAR-T cell therapy and high-volume haploidentical transplant remains limited locally. For Vietnamese families in this situation, China is not a distant option but a practical and increasingly well-documented one. This article explains when it is relevant, and how the process works from Vietnam.
This article addresses:
- What advanced cancer treatments are not yet available in Vietnam
- When China specifically adds value for Vietnamese patients
- Logistics: flights from Hanoi and Ho Chi Minh City, visa, and costs
- How Vietnam compares to Singapore and Thailand as an alternative destination
- How the process works — starting with records, not travel
What Vietnamese Patients with Blood Cancer Face Locally
Vietnam has capable haematology and oncology teams. The National Haematology and Blood Transfusion Institute (Viện Huyết học — Truyền máu Trung ương) in Hanoi and major hospitals in Ho Chi Minh City including Cho Ray Hospital handle a substantial volume of blood cancer cases and perform allogeneic bone marrow transplantation. For many patients, treatment in Vietnam is appropriate and sufficient.
The gap appears in specific advanced treatments that require regulatory approval and institutional volume that Vietnam has not yet developed at scale.
CAR-T cell therapy
CAR-T therapy has not been approved or implemented in Vietnam. Patients with relapsed or refractory B-cell leukaemia, lymphoma, or multiple myeloma who require CAR-T must travel abroad. The nearest destinations with accessible CAR-T programmes are China, Singapore, and Thailand — each with meaningfully different cost structures.
Haploidentical transplant at volume
Vietnam performs allogeneic bone marrow transplantation, but the volume and experience of haploidentical (half-matched parent or sibling) transplant for complex or relapsed cases is substantially more limited than at Chinese specialist centres. For patients who lack a matched sibling donor, or whose case involves prior treatment failures, specialist haploidentical review in China may clarify options that are not available locally.
Donor registry representation
Vietnamese patients searching for matched unrelated donors through international registries face the same structural disadvantage as other Southeast Asian patients: registries such as DKMS and NMDP/Be The Match are predominantly European in composition. Vietnamese patients from northern or central Vietnam with specific HLA profiles may have low match probabilities in these registries. This makes haploidentical family donor transplant — available through Chinese centres — a practically relevant alternative.
When China Specifically Adds Value for Vietnamese Patients
Vietnamese patients already seek treatment abroad — Singapore and Thailand are established destinations. China adds specific clinical value in situations where those destinations do not offer a clear advantage, or where China's particular experience makes a material difference.
CAR-T therapy for relapsed or refractory blood cancers
China has multiple NMPA-approved CAR-T products and established programmes for B-cell leukaemia, lymphoma, multiple myeloma, and others. Critically, the cost of CAR-T in China is typically USD 100,000–200,000 — substantially lower than in Singapore or Thailand, where pricing reflects Western-level product costs. For Vietnamese families self-funding treatment, this difference is often the decisive factor.
Haploidentical transplant when no matched donor is available
China has published the world's largest clinical experience with haploidentical transplant through the Beijing Protocol. Haploidentical donors now account for 56% of all paediatric transplants nationally — more than matched sibling and matched unrelated donors combined. See the CCBMTR 2017–2024 registry analysis for the full dataset. For Vietnamese patients whose donor search has not produced a match, haploidentical parent donor evaluation through a Chinese specialist centre is a concrete and well-documented path.
Complex paediatric blood disorders
For Vietnamese children with aplastic anaemia, thalassaemia major, paediatric leukaemia requiring transplant, or rare inherited marrow failure syndromes, Chinese paediatric haematology centres offer both the procedure volume and the published outcomes data that is difficult to access locally. Vietnam has a relatively high prevalence of thalassaemia; Chinese centres have published substantial outcomes data for thalassaemia transplantation.
Structured second opinion before major treatment decisions
An online MDT consultation with Chinese specialists can be arranged without travel — useful for Vietnamese patients who want an independent specialist review before committing to transplant, CAR-T, or other major interventions recommended by their local team.
For Vietnamese families navigating donor shortage, the haploidentical transplant resource hub provides detailed information on the Beijing Protocol, parent donor evaluation, and published outcomes.
Vietnamese family facing relapse, donor shortage, or a difficult treatment decision?
A structured case review with Chinese haematology and oncology specialists assesses whether treatment in China is clinically relevant — before any travel decision is made. No commitment required.
Request a case reviewPractical Information for Vietnamese Families
Getting to China: flights and land options
Vietnam's geographic proximity to China is a genuine practical advantage. From Hanoi, direct flights to Beijing take approximately two and a half hours; direct flights to Kunming (Yunnan province) take under two hours. From Ho Chi Minh City, connections to Beijing or Shanghai are typically four to five hours with one stop.
An overland option also exists for patients from Hanoi: crossing into Yunnan province via the northern land border. This route is longer in total travel time but may suit families transporting patients who cannot fly, or those managing complex luggage and medical equipment. Travel logistics for this route should be planned carefully in advance.
Visa and entry
Entry requirements between Vietnam and China have changed over recent years. We recommend confirming current requirements directly with the Chinese Embassy or Consulate in Hanoi or Ho Chi Minh City before making travel plans. For extended stays required by bone marrow transplant or CAR-T therapy, the coordinating hospital's international patient team can advise on available medical visa categories.
Cost context: China versus Singapore and Thailand
For Vietnamese families weighing destinations, the cost difference is often the most important practical variable. CAR-T therapy in China typically costs USD 100,000–200,000 for the product alone — substantially less than equivalent treatment in Singapore or Thailand, where pricing reflects Western-approved product cost structures. Haploidentical transplant costs in China are similarly competitive. For families funding treatment out-of-pocket, this makes China the most accessible destination for these specific treatments among the available options.
Health insurance coverage
Vietnam's social health insurance system (Bảo hiểm y tế) does not cover treatment received outside Vietnam. Private Vietnamese health insurance policies vary. Families should confirm any overseas coverage in writing before making financial commitments. In most cases, advanced treatment in China will be an out-of-pocket cost.
Language and Communication
Although Vietnamese and Chinese share historical cultural and linguistic influences, they are not mutually intelligible. At Chinese hospitals with established international patient services, coordination is typically managed in English — the shared communication language between Vietnamese families and Chinese specialist teams. Some Chinese hospitals in border regions (such as Yunnan) have Vietnamese-speaking staff, though this should not be assumed without confirmation.
Vietnamese families with limited English should identify a bilingual family member or patient advocate who can manage communications throughout the process — from records preparation and MDT review correspondence through to discharge planning and post-treatment coordination.
How the Process Works: Starting Without Travel
Despite Vietnam's proximity to China, the coordination process does not begin with travel. It begins with records.
Records compilation
Medical records from the treating team in Vietnam — pathology, imaging, bone marrow biopsy, treatment history, and blood results — are compiled and prepared for specialist review. English summaries should accompany Vietnamese-language documents where possible.
Online MDT consultation
A Chinese specialist team reviews the records remotely and produces a written recommendation. This clarifies whether treatment in China is clinically appropriate, and if so, which approach and which centre is relevant. No travel is required.
Decision and travel planning
If the MDT confirms clinical relevance, travel and logistics planning begins. The proximity of Vietnam to China — particularly the Hanoi-to-Beijing route — makes this logistically simpler than for families from other regions.
For Vietnamese families considering CAR-T therapy in China, a detailed guide to the full treatment process, eligibility, and costs is available in the CAR-T resource hub.
Supportive Care During Treatment
For Vietnamese patients undergoing intensive treatment in China, Chinese oncology centres may incorporate integrative supportive care alongside standard treatment — including traditional Chinese medicine (TCM), acupuncture for fatigue and symptom management, and nutritional support. These approaches are used as complementary care alongside chemotherapy, transplant, or CAR-T therapy — not as replacements. See the Traditional Chinese Medicine and supportive care resources for more context.
Related Guides
CAR-T and Cell Therapy in China
Approved products, eligibility, the full treatment process, costs, and how international patients access CAR-T at Chinese hospitals.
Haploidentical Transplant in China: When There Is No Matched Donor
The Beijing Protocol, parent donor options, and published outcomes for patients facing donor shortage.
Why International Families Consider China for Complex Blood Disorders
The five clinical situations — donor shortage, CAR-T access, rare paediatric disease, relapse, and second opinion — that lead international families to China.
Frequently Asked Questions
How long does it take to travel from Vietnam to Beijing or Shanghai for treatment?
From Hanoi, direct flights to Beijing take approximately two and a half hours — making it one of the shortest international journeys to a major Chinese oncology centre. From Ho Chi Minh City, direct or one-stop connections to Beijing or Shanghai are typically four to five hours. For patients who prefer not to fly, a land crossing from Hanoi into Yunnan province is also possible, though total journey time is considerably longer. For families planning extended stays, Hanoi is logistically one of the most convenient starting points in Southeast Asia for treatment in northern China.
How much does CAR-T therapy cost in China compared to Singapore or Thailand?
CAR-T therapy in China is typically priced in the range of USD 100,000–200,000 for the product cost alone — significantly lower than equivalent treatment in Singapore or Thailand, where pricing reflects Western-level product costs. For Vietnamese families planning out-of-pocket treatment, this difference is often the determining factor. Total costs should include hospitalisation, conditioning chemotherapy, monitoring, and accommodation in addition to the product price.
Full guide: CAR-T therapy costs in China for international patients →Do Vietnamese patients need a visa to enter China for medical treatment?
Visa requirements between Vietnam and China change periodically. We recommend checking the current requirements with the Chinese Embassy or Consulate in Hanoi or Ho Chi Minh City before making travel plans. For extended treatment stays that exceed a standard tourist entry period, the coordinating hospital's international patient team can typically advise on available visa categories for medical stays.
Is haploidentical bone marrow transplant available in Vietnam?
Vietnam has bone marrow transplant capability at major hospitals including the National Haematology and Blood Transfusion Institute in Hanoi. However, the volume and experience of haploidentical (half-matched) transplant — particularly for complex or relapsed cases — is substantially more limited than at high-volume Chinese specialist centres. For patients without a matched sibling donor, or for relapsed cases requiring more complex protocols, a specialist review from a Chinese haematology centre may clarify whether additional options exist.
What is the first step for a Vietnamese family considering treatment or a second opinion in China?
The process begins with records — not a flight. An online MDT consultation allows Chinese specialists to review existing medical records, imaging, and pathology remotely and produce a written recommendation on whether treatment in China is clinically relevant. No travel is required at this stage, and no commitment to proceed is implied by requesting a review.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions must be made in consultation with qualified oncologists, haematologists, or transplant physicians who have reviewed the patient's complete clinical records and current health status.
Considering treatment in China from Vietnam?
An online MDT consultation reviews your case remotely and gives a concrete recommendation — before any travel decision is made. No commitment required.
Request a case reviewFor CAR-T, donor shortage, paediatric blood disorders, and complex oncology cases — the process begins with records, not travel.